American Journal of Kidney Diseases
Volume 55, Issue 1 , Pages 50-60 , January 2010

Phase 1 Trial of Adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) Study Group

  • Melanie S. Joy, PharmD

      Affiliations

    • UNC Kidney Center and Division of Nephrology and Hypertension, University of North Carolina at Chapel Hill, Chapel Hill, NC
    • School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, NC
    • ,
  • Debbie S. Gipson, MD, MSPH

      Affiliations

    • UNC Kidney Center and Division of Nephrology and Hypertension, University of North Carolina at Chapel Hill, Chapel Hill, NC
    • ,
  • Leslie Powell, RN, CPNP

      Affiliations

    • UNC Kidney Center and Division of Nephrology and Hypertension, University of North Carolina at Chapel Hill, Chapel Hill, NC
    • ,
  • Jacqueline MacHardy, BS

      Affiliations

    • UNC Kidney Center and Division of Nephrology and Hypertension, University of North Carolina at Chapel Hill, Chapel Hill, NC
    • ,
  • J. Charles Jennette, MD

      Affiliations

    • Department of Pathology, University of North Carolina at Chapel Hill, Chapel Hill, NC
    • ,
  • Suzanne Vento, RN

      Affiliations

    • Division of Nephrology, Schneider Children's Hospital of North Shore-LIJ Health System, New Hyde Park, NY
    • ,
  • Cynthia Pan, MD

      Affiliations

    • Departments of Pediatrics and Medicine, Division of Nephrology, Medical College of Wisconsin, Milwaukee, WI
    • ,
  • Virginia Savin, MD

      Affiliations

    • Departments of Pediatrics and Medicine, Division of Nephrology, Medical College of Wisconsin, Milwaukee, WI
    • ,
  • Allison Eddy, MD

      Affiliations

    • Division of Nephrology, Seattle Children's Hospital, Seattle, WA
    • ,
  • Agnes B. Fogo, MD

      Affiliations

    • Department of Pathology, Vanderbilt University Medical Center, Nashville, TN
    • ,
  • Jeffrey B. Kopp, MD

      Affiliations

    • Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, Kidney Diseases Branch, National Institutes of Health, Bethesda, MD
    • ,
  • Daniel Cattran, MD, FRCPC

      Affiliations

    • Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada
    • ,
  • Howard Trachtman, MD

      Affiliations

    • Division of Nephrology, Schneider Children's Hospital of North Shore-LIJ Health System, New Hyde Park, NY
    • Corresponding Author InformationAddress correspondence to Howard Trachtman, MD, Schneider Children's Hospital, Division of Nephrology, 269-01 76th Ave, New Hyde Park, NY 11040

Received 21 April 2009 ,Accepted 17 August 2009.

References 

  1. Lopez-Olivo MA, Kallen MA, Ortiz Z, Skidmore B, Suarez-Almazor ME. Quality appraisal of clinical practice guidelines and consensus statements on the use of biologic agents in rheumatoid arthritis: a systemic review. Arthritis Rheum. 2008;59:1625–1638
  2. Shah SB, Hanauer SB. Risks and benefits of the use of concomitant immunosuppressives and biologics in inflammatory bowel disease. Rev Gastroenterol Disord. 2008;8:159–168
  3. Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359:810–821
  4. Felderman M. Many cytokines are very useful therapeutic targets in disease. J Clin Invest. 2008;118:3533–3536
  5. Li X, Magenheimer BS, Xia S, et al. A tumor necrosis factor-α-mediated pathway promoting autosomal dominant polycystic kidney disease. Nat Med. 2008;14:863–868
  6. LeBerre L, Herve C, Buzelin F, Usal C, Soulillou JP, Dantal J. Renal macrophage activation and Th2 polarization precedes the development of nephrotic syndrome in Buffalo/Mna rats. Kidney Int. 2005;68:2079–2090
  7. Suranyi MG, Guasch A, Hall BM, Myers BD. Elevated levels of tumor necrosis factor-α in the nephrotic syndrome in humans. Am J Kidney Dis. 1993;21:251–259
  8. Kacprzyk F, Chrzanowski W. Tumor necrosis factor (TNF) and interleukin-6 (IL-6) on patients with glomerulonephritis. Pol Arch Med Wewn. 1996;96:224–233
  9. Tain YL, Chen TY, Yang KD. Implications of serum TNF-β and IL-13 in the treatment response of childhood nephrotic syndrome. Cytokine. 2003;21:155–159
  10. Lama G, Luongo I, Tirinio G, Borriello A, Carangio C, Salsano ME. T-Lymphocyte populations and cytokines in childhood nephrotic syndrome. Am J Kidney Dis. 2002;39:958–965
  11. Bakr A, Shokeir M, El-Chenawi F, El-Husseini F, Abdel-Rahman A, El-Ashry R. Tumor necrosis factor-α production from mononuclear cells in nephrotic syndrome. Pediatr Nephrol. 2003;18:516–520
  12. Niemir ZI, Ondracek M, Dworacki G, et al. In situ regulation of IL-10 reflects the activity of human glomerulonephritides. Am J Kidney Dis. 1998;32:80–92
  13. McCarthy ET, Sharma R, Sharma M, et al. TNF-α increases albumin permeability of isolated rat glomeruli through the generation of superoxide. J Am Soc Nephrol. 1998;9:433;438
  14. Futrakul FN, Panichakul T, Butthep P, et al. Ganoderma lucidum suppresses endothelial cell cytotoxicity and proteinuria in persistent proteinuric focal segmental glomerulosclerosis. Clin Hemorheol Microcirc. 2004;31:267–272
  15. Sharma M, Li JZ, Sharma R, et al. Inhibitory effect of Tripterygium wilfordii multiglycoside on increased glomerular albumin permeability in vitro. Nephrol Dial Transplant. 1997;12:2064–2068
  16. Raveh D, Shemesh O, Ashkenazi YJ, Winkler R, Barak V. Tumor necrosis factor-α blocking agent as a treatment for nephrotic syndrome. Pediatr Nephrol. 2004;19:1281–1284
  17. Chin G, Luxton G, Harvey JM. Infliximab and nephrotic syndrome. Nephrol Dial Transplant. 2005;20:2824–2826
  18. Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis. Nephrol Dial Transplant. 2005;20:1400–1406
  19. Joy MS, Gipson DS, Dike M, et al. Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group. Clin J Am Soc Nephrol. 2009;4:39–47
  20. Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12
  21. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303–332
  22. Weisman MH, Moreland LW, Furst DE, et al. Efficacy, pharmacokinetics, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003;25:1700–1721
  23. Den Broeder A, van de Putte L, Rau R, et al. A single-dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol. 2002;29:2288–2298
  24. Adalimumab [investigator brochure]. Abbott Park, IL: Abbott Laboratories; June 2003;
  25. Lionski S, Siamopoulos K, Theodoirou I, et al. Inhibition of tumor necrosis factor alpha in idiopathic membranous nephropathy: a pilot study. Nephrol Dial Transplant. 2009;24:2144–2150
  26. Ducloux D, Bresson-Vautrin C, Chalopin J. Use of pentoxifylline in membranous nephropathy. Lancet. 2001;357:1672–1673
  27. Ellis D, Buffone GJ. Protein clearances and selectivity determinations in childhood nephrosis: a reappraisal. Clin Chem. 1981;27:1397–1400
  28. Bartelds GM, Wijbrandts CA, Nurmohamen MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66:921–926
  29. Wallois RS. Tumor necrosis factor antagonists: structure, function, and tuberculosis risk. Lancet Infect Dis. 2008;8:601–611
  30. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized clinical trial. JAMA. 2006;295:2275–2285
  31. Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine. 2007;86:242–251
  32. Frank KM, Hogarth K, Miler JL, et al. Investigation of the cause of death in a gene-therapy trial. N Engl J Med. 2009;361:161–169
  33. Leroy S, Guigonia V, Bruckner D, et al. Successful anti-TNF-α treatment in a child with posttransplant recurrent focal segmental glomerulosclerosis. Am J Transplant. 2009;9:858–861
  34. Ernandez T, Mayadas TN. Immunoregulatory role of TNF-α in inflammatory kidney diseases. Kidney Int. 2009;76:262–276

 Originally published online as doi:10.1053/j.ajkd.2009.08.019 on November 23, 2009.

 Trial registration: www.ClinicalTrials.gov; study number: NCT00814255.

PII: S0272-6386(09)01188-3

doi: 10.1053/j.ajkd.2009.08.019

American Journal of Kidney Diseases
Volume 55, Issue 1 , Pages 50-60 , January 2010

Article Tools

* Image Usage & Resolution